Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-{4-methyl-3-[(3-pyrimidin-4-ylpyridin-2-yl)amino]phenyl}-3-(trifluoromethyl)benzamide
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Small Molecules
01
Overview
N-{4-methyl-3-[(3-pyrimidin-4-ylpyridin-2-yl)amino]phenyl}-3-(trifluoromethyl)benzamide is an experimental small molecule belonging to the benzanilide class. It has been studied as a potent inhibitor of the angiopoietin‑1 receptor (Tie2), a tyrosine kinase involved in angiogenesis and vascular maturation. The compound demonstrates nanomolar inhibitory activity against Tie2 in biochemical assays, suggesting potential utility in diseases where modulation of angiogenesis is relevant, such as cancer or ocular neovascular disorders. The molecule has been referenced under several research code names and identifiers but does not have an approved therapeutic indication or brand name at this time[1][5].
- Other names
- N-(4-methyl-3-{[3-(pyrimidin-4-yl)pyridin-2-yl]amino}phenyl)-3-(trifluoromethyl)benzamideBenzamide, N-[4-methyl-3-[ [3-(4-pyrimidinyl)-2-pyridinyl]amino ]phenyl]-3-(trifluoromethyl)-
02
Targets
TEK (Tie2)
Beyond the preview
Go deeper on N-{4-methyl-3-[(3-pyrimidin-4-ylpyridin-2-yl)amino]phenyl}-3-(trifluoromethyl)benzamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-{4-methyl-3-[(3-pyrimidin-4-ylpyridin-2-yl)amino]phenyl}-3-(trifluoromethyl)benzamide.